Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer

Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficacy of 6-month vs. 12-month adjuvant trastuzumab use in patients with HER2+ early breast cancer. In this interview, Robert Coleman, MBBS, MD, FRCP, FRCPE, of the University of Sheffield, Sheffield, UK, discusses the results of this study and their wider implications.This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.